Brenton Pennicooke1,2, Ilya Laufer1, Arjun Sahgal3, Peter P Varga4, Ziya L Gokaslan5, Mark H Bilsky1, Yoshiya J Yamada6. 1. Department of Neurological Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Neurological Surgery, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY. 3. Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. 4. Department of Spinal Disorders, National Health Center, Budapest, Hungary. 5. Department of Neurosurgery, The Warren Alpert Medical School of Brown University, Rhode Island Hospital and Norman Prince Neurosciences Institute, Providence, RI. 6. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
STUDY DESIGN: Systematic literature review. OBJECTIVE: To assess the toxicity, common radiation doses, and local control (LC) rates of radiation therapy for chordoma of the spine and sacrum and identify the difference in LC and toxicity between adjuvant, salvage, and primary therapy using radiation. SUMMARY OF BACKGROUND DATA: Chordoma of the spine is typically a low-grade malignant tumor thought to be relatively radioresistant with a high rate of local recurrence and the potential for metastases. Improved results of modern radiation therapy in the treatment of chordoma support exploration of its role in the management of primary/de novo chordoma or recurrent chordoma. METHODS: We conducted a systematic literature review using PubMed and Embase databases to assess information available regarding the toxicity, LC rates, and overall survival (OS) rates for adjuvant, salvage, and primary radiation therapy for spinal and sacral chordoma. RESULTS: A total of 40 articles were reviewed. Evidence quality was low or very low. The highest rates of LC and OS were with early adjuvant RT for primary/de novo disease. Salvage RT for recurrent disease has very small cohorts and thus strong conclusions were not able be made. CONCLUSION: The use of pre- and/or post-operative photon image-guided radiotherapy (IGRT), proton or carbon ion therapy should be considered for patients undergoing surgery for the treatment of primary and recurrent chordomas in the mobile spine and sacrum, since these RT modalities may improve local control. Preoperative evaluation by the surgeon and radiation oncologist should be used to formulate a cohesive treatment plan.The use of photon IGRT or carbon ion therapy as the primary treatment of chordoma, when currently in its developmental stage, shows promise and requires clear delineation of toxicity profile and long-term local control. LEVEL OF EVIDENCE: 2.
STUDY DESIGN: Systematic literature review. OBJECTIVE: To assess the toxicity, common radiation doses, and local control (LC) rates of radiation therapy for chordoma of the spine and sacrum and identify the difference in LC and toxicity between adjuvant, salvage, and primary therapy using radiation. SUMMARY OF BACKGROUND DATA: Chordoma of the spine is typically a low-grade malignant tumor thought to be relatively radioresistant with a high rate of local recurrence and the potential for metastases. Improved results of modern radiation therapy in the treatment of chordoma support exploration of its role in the management of primary/de novo chordoma or recurrent chordoma. METHODS: We conducted a systematic literature review using PubMed and Embase databases to assess information available regarding the toxicity, LC rates, and overall survival (OS) rates for adjuvant, salvage, and primary radiation therapy for spinal and sacral chordoma. RESULTS: A total of 40 articles were reviewed. Evidence quality was low or very low. The highest rates of LC and OS were with early adjuvant RT for primary/de novo disease. Salvage RT for recurrent disease has very small cohorts and thus strong conclusions were not able be made. CONCLUSION: The use of pre- and/or post-operative photon image-guided radiotherapy (IGRT), proton or carbon ion therapy should be considered for patients undergoing surgery for the treatment of primary and recurrent chordomas in the mobile spine and sacrum, since these RT modalities may improve local control. Preoperative evaluation by the surgeon and radiation oncologist should be used to formulate a cohesive treatment plan.The use of photon IGRT or carbon ion therapy as the primary treatment of chordoma, when currently in its developmental stage, shows promise and requires clear delineation of toxicity profile and long-term local control. LEVEL OF EVIDENCE: 2.
Authors: Péter Pál Varga; Zsolt Szövérfi; Charles G Fisher; Stefano Boriani; Ziya L Gokaslan; Mark B Dekutoski; Dean Chou; Nasir A Quraishi; Jeremy J Reynolds; Alessandro Luzzati; Richard Williams; Michael G Fehlings; Niccole M Germscheid; Aron Lazary; Laurence D Rhines Journal: Eur Spine J Date: 2014-12-23 Impact factor: 3.134
Authors: Matthias Uhl; Thomas Welzel; Alexandra Jensen; Malte Ellerbrock; Thomas Haberer; Oliver Jäkel; Klaus Herfarth; Jürgen Debus Journal: Strahlenther Onkol Date: 2015-03-04 Impact factor: 3.621
Authors: M Austin-Seymour; J Munzenrider; M Goitein; L Verhey; M Urie; R Gentry; S Birnbaum; D Ruotolo; P McManus; S Skates Journal: J Neurosurg Date: 1989-01 Impact factor: 5.115
Authors: Kai-Uwe Lewandrowski; Andrew C Hecht; Thomas F DeLaney; Peter A Chapman; Francis J Hornicek; Frank X Pedlow Journal: Spine (Phila Pa 1976) Date: 2004-05-15 Impact factor: 3.468
Authors: Silvia Stacchiotti; Paolo Giovanni Casali; Salvatore Lo Vullo; Luigi Mariani; Elena Palassini; Mario Mercuri; Marco Alberghini; Silvana Pilotti; Licciana Zanella; Alessandro Gronchi; Piero Picci Journal: Ann Surg Oncol Date: 2009-10-22 Impact factor: 5.344
Authors: Yoshiya Yamada; Ilya Laufer; Brett W Cox; D Michael Lovelock; Robert G Maki; Joan M Zatcky; Patrick J Boland; Mark H Bilsky Journal: Neurosurgery Date: 2013-10 Impact factor: 4.654
Authors: Adam L Holtzman; Ronny L Rotondo; Michael S Rutenberg; Daniel J Indelicato; Alexandra De Leo; Dinesh Rao; Jeet Patel; Christopher G Morris; William M Mendenhall Journal: Int J Part Ther Date: 2021-06-25